| Cyclin-dependent kinase-9 is a therapeutic target in MYC-expressing diffuse large B-cell lymphoma T Hashiguchi, N Bruss, S Best, V Lam, O Danilova, CJ Paiva, J Wolf, ... Molecular cancer therapeutics 18 (9), 1520-1532, 2019 | 47 | 2019 |
| Targeting ubiquitin-activating enzyme induces ER stress–mediated apoptosis in B-cell lymphoma cells S Best, T Hashiguchi, A Kittai, N Bruss, C Paiva, C Okada, T Liu, A Berger, ... Blood advances 3 (1), 51-62, 2019 | 47 | 2019 |
| SYK inhibition thwarts the BAFF-B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia C Paiva, TA Rowland, B Sreekantham, C Godbersen, SR Best, P Kaur, ... Haematologica 102 (11), 1890, 2017 | 33 | 2017 |
| Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells S Best, V Lam, T Liu, N Bruss, A Kittai, OV Danilova, S Murray, A Berger, ... Leukemia 35 (1), 156-168, 2021 | 31 | 2021 |
| Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells S Best, T Liu, N Bruss, A Kittai, A Berger, AV Danilov Leukemia & Lymphoma, 2019 | 13 | 2019 |
| Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia V Lam, S Best, A Kittai, K Orand, SE Spurgeon, T Liu, AV Danilov British Journal of Clinical Pharmacology 88 (2), 836-841, 2022 | 7 | 2022 |
| Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies AS Kittai, S Best, B Thurlow, V Lam, T Hashiguchi, S Goodyear, ... haematologica 106 (7), 2022, 2021 | 6 | 2021 |
| Neddylation and anti-tumor immunity X Wang, S Best, AV Danilov Oncotarget 12 (21), 2227, 2021 | 5 | 2021 |
| Pharmacologic inhibition of SUMO-activating enzyme (SAE) with TAK-981 augments interferon signaling and regulates T cell differentiation in ex vivo studies of chronic … V Lam, SR Best, N Bruss, T Liu, TH Rowland, D Huszar, A Danilov Blood 134, 1760, 2019 | 5 | 2019 |
| NEDD8-activating enzyme inhibition induces cell cycle arrest and anaphase catastrophe in malignant T-cells AS Kittai, OV Danilova, V Lam, T Liu, N Bruss, S Best, G Fan, AV Danilov Oncotarget 12 (20), 2068, 2021 | 4 | 2021 |
| T cell–intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia V Lam, C Roleder, T Liu, N Bruss, S Best, X Wang, T Phillips, G Shouse, ... Molecular cancer therapeutics 22 (9), 1040-1051, 2023 | 3 | 2023 |
| SYK inhibitor entospletinib in combination with Obinutuzumab demonstrates efficacy in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) AS Kittai, SR Best, B Thurlow, B Gokcora, A Stadnik, R MacKinnon, ... Blood 134, 4295, 2019 | 3 | 2019 |
| TAK-243, a small molecule inhibitor of ubiquitin-activating enzyme (UAE), induces ER stress and apoptosis in diffuse large B-cell lymphoma (DLBCL) cells SR Best, C Paiva, T Rowland, B Sreekantham, SE Spurgeon, A Berger, ... Blood 130, 1533, 2017 | 2 | 2017 |
| TAK-243, a Small Molecule Inhibitor of Ubiquitin-Activating Enzyme (UAE), Induces ER Stress and Apoptosis in CLL Cells SR Best, T Rowland, C Paiva, N Bruss, SE Spurgeon, A Berger, ... Blood 132, 1867, 2018 | 1 | 2018 |
| Pevonedistat, a small molecule inhibitor of NEDD8-activating enzyme (NAE), induces cell cycle deregulation, anaphase catastrophe, and apoptosis in T-cell lymphoma cells A Kittai, SR Best, T Rowland, N Bruss, C Okada, AV Danilov Blood 132, 1667, 2018 | 1 | 2018 |
| Selective targeting cyclin-dependent kinase-9 (CDK9) antagonizes survival of neoplastic B-cells via deregulation of c-MYC and MCL-1 A Danilov, T Rowland, C Paiva, S Best, B Sreekantham, J Rowley, ... LEUKEMIA & LYMPHOMA 58, 25-26, 2017 | 1 | 2017 |
| Pharmacologic Inhibition of SUMO-Activating Enzyme Potentiates Interferon Response and T Cell-Mediated Anti-Tumor Immunity in Chronic Lymphocytic Leukemia (CLL) and Lymphoma Models V Lam, X Wang, SR Best, N Bruss, T Liu, O Danilova, T Siddiqi, ... Blood 138, 3719, 2021 | | 2021 |
| Neddylation Pathway Regulates Treg Differentiation and T Cell Function in Chronic Lymphocytic Leukemia (CLL) Ex Vivo and Murine In Vivo Studies SR Best, V Lam, N Bruss, TH Rowland, AS Kittai, T Liu, AJ Berger, ... Blood 134, 4313, 2019 | | 2019 |
| Immunomodulatory Effects of Pevonedistat, a NEDD8-Activating Enzyme (NAE) Inhibitor, in Chronic Lymphocytic Leukemia (CLL) SR Best, A Kittai, T Rowland, N Bruss, SE Spurgeon, A Berger, A Moran, ... Blood 132, 2946, 2018 | | 2018 |
